Tyrosine kinase receptor

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 45: Line 45:
**[[4asz]] – hTRK-B kinase domain<BR />
**[[4asz]] – hTRK-B kinase domain<BR />
**[[4at3]], [[4at4]], [[4at5]] – hTRK-B kinase domain + inhibitor<BR />
**[[4at3]], [[4at4]], [[4at5]] – hTRK-B kinase domain + inhibitor<BR />
-
**[[42mfq]] – hTRK-B kinase domain + FRS2A - NMR<BR />
+
**[[4mfq]] – hTRK-B kinase domain + FRS2A - NMR<BR />
*TRK-C or NT-3 growth factor receptor
*TRK-C or NT-3 growth factor receptor
Line 52: Line 52:
**[[4pbv]], [[4pbw]] – hTRK-C extracellular domain (mutant) + tyrosine phosphatase s<BR />
**[[4pbv]], [[4pbw]] – hTRK-C extracellular domain (mutant) + tyrosine phosphatase s<BR />
**[[3v5q]], [[4ymj]], [[6kzc]], [[6kzd]] – hTRK-C kinase domain + inhibitor<BR />
**[[3v5q]], [[4ymj]], [[6kzc]], [[6kzd]] – hTRK-C kinase domain + inhibitor<BR />
 +
 +
*TrkA potassium uptake protein
 +
 +
**[[4j9v]] – VpTrkA + ATP – ''Vibrio parahaemolyticus''<br />
 +
**[[6v4j]], [[6v4l]] – VpTrkA + TrkH + ATP <br />
 +
**[[6v4k]] – VpTrkA + TrkH + ADP<br />
 +
**[[4j9u]] – VpTrkA + TrkH + NAD<br />
 +
 +
*TrkH potassium uptake protein
 +
 +
**[[3pjz]] – VpTrkH<br />
}}
}}
== References ==
== References ==
<references/>
<references/>
[[Category:Topic Page]]
[[Category:Topic Page]]

Revision as of 08:46, 14 June 2022

Human TRK-A kinase domain complex with inhibitor, glycerol and sulfate (PDB code 4yne)

Drag the structure with the mouse to rotate

3D Structures tyrosine kinase receptor

Updated on 14-June-2022

References

  1. Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018 Feb 19;17(1):58. doi: 10.1186/s12943-018-0782-4. PMID:29455648 doi:http://dx.doi.org/10.1186/s12943-018-0782-4
  2. Deinhardt K, Chao MV. Trk receptors. Handb Exp Pharmacol. 2014;220:103-19. doi: 10.1007/978-3-642-45106-5_5. PMID:24668471 doi:http://dx.doi.org/10.1007/978-3-642-45106-5_5
  3. Cassol CA, Winer D, Liu W, Guo M, Ezzat S, Asa SL. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas. Mod Pathol. 2014 Aug;27(8):1050-62. doi: 10.1038/modpathol.2013.233. Epub 2014, Jan 3. PMID:24390213 doi:http://dx.doi.org/10.1038/modpathol.2013.233
  4. Choi HS, Rucker PV, Wang Z, Fan Y, Albaugh P, Chopiuk G, Gessier F, Sun F, Adrian F, Liu G, Hood T, Li N, Jia Y, Che J, McCormack S, Li A, Li J, Steffy A, Culazzo A, Tompkins C, Phung V, Kreusch A, Lu M, Hu B, Chaudhary A, Prashad M, Tuntland T, Liu B, Harris J, Seidel HM, Loren J, Molteni V. (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors. ACS Med Chem Lett. 2015 Mar 16;6(5):562-7. doi: 10.1021/acsmedchemlett.5b00050., eCollection 2015 May 14. PMID:26005534 doi:http://dx.doi.org/10.1021/acsmedchemlett.5b00050
  5. Wehrman T, He X, Raab B, Dukipatti A, Blau H, Garcia KC. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Neuron. 2007 Jan 4;53(1):25-38. PMID:17196528 doi:10.1016/j.neuron.2006.09.034

Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Alexander Berchansky

Personal tools